TLC to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit

Rhea-AI Summary

SOUTH SAN FRANCISCO and TAIPEI, Sept. 21, 2020 – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company, announced that President George Yeh and CMO Dr. George Spencer-Green will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 23, 2020, at 9:10am ET. The 40-minute presentation will cover company updates and data analyses on its pain programs, TLC599 and TLC590. The corporate presentation is accessible on the TLC website.

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 21, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 23, 2020 at 9:10am ET.

The 40-minute live presentation will include a company overview and update by Mr. Yeh, with analyses of data on TLC’s pain programs – TLC599 and TLC590 – by Dr. Spencer-Green. During the virtual conference, which takes place September 21-23, 2020, TLC will also be participating in one-on-one sessions.

The corporate presentation is available on the TLC website at www.tlcbio.com in the Investors section, under News & Events.

About TLC

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of a diverse, wholly owned portfolio of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™), including BioSeizer^® sustained release technology and NanoX™ active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval. Other risks are described in the Risk Factors section of TLC’s annual report on Form 20-F for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on TLC’s expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

FAQ

When is TLC presenting at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit?

TLC is presenting on September 23, 2020, at 9:10am ET.

Who will represent TLC at the Med Tech Summit?

President George Yeh and CMO Dr. George Spencer-Green will represent TLC.

What will TLC discuss in their presentation at the summit?

TLC will provide a company overview and update, along with data on their pain programs TLC599 and TLC590.

Where can I find TLC's corporate presentation?

The corporate presentation is available on TLC's website in the Investors section under News & Events.

What is TLC's focus as a clinical-stage pharmaceutical company?

TLC focuses on developing novel nanomedicines to address unmet medical needs.